CurrentAmeriHealth Caritas VIP CarePolicy CCP.1562

Autoimmune Disease Diagnostic Panel Testing

Customize your policy alerts

Sign up for amerihealth_caritas_vip_care Policy CCP.1562 alerts

Get alerted when Policy CCP.1562 changes without checking for updates manually.

Monitor payer policy activity

Receive email alerts as soon as relevant payer policies are published or updated.

Coverage of multianalyte and proprietary algorithm-based autoimmune diagnostic panels, including AVISE-type panels and cell-bound complement activation product panels, when used for diagnosis, differentiation, prognosis, risk stratification, or management of systemic lupus erythematosus and related autoimmune diseases.

Policy Summary

PayerAmeriHealth Caritas VIP Care

PolicyAutoimmune Disease Diagnostic Panel Testing

Policy CodePolicy CCP.1562

Change TypeNo material change

Effective DateJuly 1, 2026

Last ReviewJun 1, 2026

Next Review DateOctober 1, 2027

Key ActionDo not submit claims for autoimmune diagnostic panel testing used for diagnosis, differentiation, prognosis, risk stratification, or management of autoimmune disease.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

5Related laboratory codes listed

Not coveredCoverage stance

OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

CurrentAmeriHealth Caritas VIP CarePolicy CCP.1562

Autoimmune Disease Diagnostic Panel Testing

Customize your policy alerts

Sign up for amerihealth_caritas_vip_care Policy CCP.1562 alerts

Get alerted when Policy CCP.1562 changes without checking for updates manually.

Monitor payer policy activity

Receive email alerts as soon as relevant payer policies are published or updated.

Policy Summary

PayerAmeriHealth Caritas VIP Care

PolicyAutoimmune Disease Diagnostic Panel Testing

Policy CodePolicy CCP.1562

Change TypeNo material change

Effective DateJuly 1, 2026

Last ReviewJun 1, 2026

Next Review DateOctober 1, 2027

Key ActionDo not submit claims for autoimmune diagnostic panel testing used for diagnosis, differentiation, prognosis, risk stratification, or management of autoimmune disease.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

5Related laboratory codes listed

Not coveredCoverage stance

Autoimmune Diagnostic Panel Coverage

Autoimmune Diagnostic Panel Testing

Autoimmune diagnostic panel testing is not medically necessary for any of the listed uses.

Autoimmune diagnostic panel testing, including multianalyte assay panels, proprietary algorithm-based autoimmune panels, AVISE-type autoimmune diagnostic panels, and cell-bound complement activation product panels, is not medically necessary for the diagnosis, differentiation, prognosis, risk stratification, or management of autoimmune disease, including systemic lupus erythematosus and related connective tissue diseases.

This policy addresses autoimmune disease diagnostic panel testing, including multianalyte assay panels, proprietary algorithm-based autoimmune panels, AVISE-type autoimmune diagnostic panels, and cell-bound complement activation product panels.

The testing is investigational and not clinically proven. Therefore, it is not medically necessary for members when used to diagnose, differentiate, determine prognosis, perform risk stratification, or manage autoimmune disease, including systemic lupus erythematosus and related connective tissue diseases.

Related Laboratory Codes

Related codesCPTNot Covered

0062U	Autoimmune (systemic lupus erythematosus), IgG and IgM analysis of 80 biomarkers, utilizing serum, algorithm reported with a risk score.
0312U	Autoimmune diseases (e.g., systemic lupus erythematosus [SLE]), analysis of 8 IgG autoantibodies and 2 cell-bound complement activation products using enzyme-linked immunosorbent immunoassay (ELISA), flow cytometry, and indirect immunofluorescence, serum, or plasma and whole blood, individual components reported along with an algorithmic SLE-likelihood assessment.
0446U	Autoimmune diseases (systemic lupus erythematosus [SLE]), analysis of 10 cytokine soluble mediator biomarkers by immunoassay, plasma, individual components reported with an algorithmic risk score for current disease activity.
0447U	Autoimmune diseases (systemic lupus erythematosus [SLE]), analysis of 11 cytokine soluble mediator biomarkers by immunoassay, plasma, individual components reported with an algorithmic prognostic risk score for developing a clinical flare.
81599	Unlisted multianalyte assay with algorithmic analysis.

Coverage and Claim Handling

Denial Risk

Autoimmune diagnostic panels are not covered

Do not expect coverage for autoimmune disease diagnostic panel testing. Claims are denied because this testing is considered investigational, not clinically proven, and not medically necessary when used for diagnosis, differentiation, prognosis, risk stratification, or management of autoimmune disease, including systemic lupus erythematosus and related connective tissue diseases.

Clinical and Laboratory Background

Autoimmune disease diagnostic panels combine multiple serum or cell-associated biomarkers with an interpretive score or proprietary algorithm. These blood-based tests are generally intended to produce a composite or algorithmic result for suspected systemic lupus erythematosus and related connective tissue diseases.

Key Terms

Autoimmune disease diagnostic panel

DefinitionBlood-based testing that combines multiple serum or cell-associated biomarkers with an interpretive score or proprietary algorithm.

Multianalyte assay panel

DefinitionA laboratory result generally reported as a composite score or tiered result intended to supplement, rather than replace, clinical assessment.

Investigational/not clinically proven

Policy classificationTesting is considered investigational, not clinically proven, and not medically necessary for the diagnosis, differentiation, prognosis, risk stratification, or management of autoimmune disease, including systemic lupus erythematosus and related connective tissue diseases.

Excluded Testing Categories

The following testing categories are not covered as medically necessary: multianalyte assay panels for autoimmune disease; proprietary algorithm-based autoimmune panels; AVISE, AVISE Lupus, and AVISE Connective Tissue Disease panels; and cell-bound complement activation product panels.